Trial Profile
Master Protocol of Three Randomized, Double-blind, Placebo Controlled, Multi-center, Parallel-group Studies of Dupilumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment in Patients naïve to Omalizumab and in Patients Who Are Intolerant or Incomplete Responders to Omalizumab
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 16 Apr 2024
Price :
$35
*
At a glance
- Drugs Dupilumab (Primary) ; Antihistamines
- Indications Chronic urticaria
- Focus Registrational; Therapeutic Use
- Acronyms CUPID; LIBERTY-CSU CUPID Study A
- Sponsors Sanofi
- 16 Apr 2024 Status changed from recruiting to active, no longer recruiting.
- 09 Apr 2024 Planned End Date changed from 29 Nov 2024 to 24 Oct 2024.
- 09 Apr 2024 Planned primary completion date changed from 15 Mar 2024 to 22 Aug 2024.